Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) were developed as antidiabetic agents, but accumulating evidence has shown their beneficial effects on the cardiovascular system. Analyses of the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Boyang, Zhao, Xiaoya, Zhou, Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8028072/
https://www.ncbi.nlm.nih.gov/pubmed/33827579
http://dx.doi.org/10.1186/s12933-021-01266-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8028072/
https://www.ncbi.nlm.nih.gov/pubmed/33827579
http://dx.doi.org/10.1186/s12933-021-01266-x

Ejemplares similares